Brought to you by 
Bradley buys Quintiles' Bioglan Pharmaceuticals for $183mm
11 Aug 2004
Executive Summary
Bradley Pharmaceuticals (brand-name prescription and OTC products in the areas of dermatology, nutrition, and gastroenterology) is acquiring the assets of dermatology company Bioglan Pharmaceuticals, a subsidiary of CRO Quintiles Transnational, for $183mm in cash.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bradley buys Quintiles' Bioglan Pharmaceuticals for $183mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice